Pr. Dan Peer

Dan Peer is a professor and director of the Precision Nanomedicine Laboratory atTel Aviv University (TAU). He is also the Vice President of Research and Development at Tel Aviv University. From 2017 to present, he is the founder and executive director of the SPARK Program in Translational Medicine at TAU.
Professor Peer’s work was among the first to demonstrate systemic delivery of RNA molecules using immune-targeted nano-deliverers and he pioneered the use of RNA interference (RNAi) in immune cells. His laboratory was the first to demonstrate systemic and cell-specific delivery of modified mRNAs to an animal to induce therapeutic gene expression of desired proteins. This has huge implications in cancer, inflammation and infectious diseases (e.g. COVID 19 mRNA vaccines). In addition, his lab was the first to demonstrate high-efficiency, systemic, cell-specific therapeutic genome editing in cancer.
Professor Peer holds more than 130 pending or granted patents. Some of them have been licensed to several pharmaceutical companies and one of them is currently under registration (as a new biologic drug for inflammatory bowel disease). In addition, based on his work, five spin-off companies have been created to introduce innovative personalized medicine into clinical practice.
Professor Peer has received more than 30 awards and honors and serves on the scientific advisory boards and boards of directors of more than 15 companies, as well as on the editorial boards of more than 20 journals.